Allogeneic immunotherapy for relapsed multiple myeloma

• Verfasst von: Görner, Martin [VerfasserIn]
• Verfasst von: Höpfner, Sabine [VerfasserIn]
• Verfasst von: Goldschmidt, Hartmut [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Titel: Allogeneic immunotherapy for relapsed multiple myeloma
• Titelzusatz: role of matched unrelated donors
• Verf.angabe: M. Görner, S. Höpfner, H. Goldschmidt & A.D. Ho
• E-Jahr: 2002
• Jahr: June 2002
• Umfang: 3 S.
• Fussnoten: Gesehen am 11.02.2022
• Titel Quelle: Enthalten in: The Chinese-german journal of clinical oncology
• Ort Quelle: Berlin : Springer, 2002
• Jahr Quelle: 2002
• Band/Heft Quelle: 1(2002), 2, Seite 72-74
• ISSN Quelle: 1613-9089
• DOI: doi:10.1007/BF02851737
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1789451043

Abstract

Existence of a graft-versus-myeloma effect has been well documented by responses to donor lymphocyte infusions and longterm survival after allogeneic bone marrow transplantation. The development of non-myeloablative conditioning regimens allows utilization of allogeneic effects in patients usually not suitable for myeloablative allogeneic transplantation, such as older and heavily pretreated patients. In a small series of 11 patients with multiple myeloma relapsing after autologous transplantation, we show that conditioning with low-dose total body irradiation in combination with fludarabine allows stable engraftment after matched unrelated donor transplantation and is tolerated with acceptable transplant-related morbidity and mortality. With a short median follow-up of 225 days, disease control was achieved only for patients responding to conventional treatment prior to allografting. Future studies with longer follow-up have to define the role of non-myeloablative allogeneic transplantation from unrelated donors as consolidation for patients responding to salvage therapy.